• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Liu Xiqiao was granted 43,000 shares

    7/29/22 4:31:00 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Liu Xiqiao

    (Last) (First) (Middle)
    ROOM 3310, NORTH TOWER, ZHENGDA CENTER
    NO.20, JINHE EAST RD, CHAOYANG DISTRICT

    (Street)
    BEIJING F4 100020

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SHINECO, INC. [ SISI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    COO
    3. Date of Earliest Transaction (Month/Day/Year)
    07/27/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/27/2022 A 43,000(1) A $0 43,000(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On July 27, 2022 the Reporting Person was issued 43,000 restricted shares of Issuer's common stock under the 2022 Equity Incentive Plan.
    /s/ Xiqiao Liu 07/29/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SISI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

    BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad

    9/12/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

    BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical suppor

    9/10/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

    BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agree

    8/27/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

    3 - SHINECO, INC. (0001300734) (Issuer)

    4/24/25 4:05:15 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Yan Chi Keung

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Wang Xiaohui

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:16 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    SEC Filings

    View All

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - SHINECO, INC. (0001300734) (Filer)

    7/30/25 7:35:46 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEF 14C filed by Shineco Inc.

    DEF 14C - SHINECO, INC. (0001300734) (Filer)

    7/15/25 9:00:11 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - SHINECO, INC. (0001300734) (Filer)

    7/9/25 4:05:57 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    View All

    Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

    BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. The Division is expected to use blockchain technol

    8/13/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Future FinTech Announces the Appointment of Hu Li as the New CEO

    NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

    8/9/24 9:00:00 AM ET
    $FTFT
    $SISI
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Announces the Appointment of Two New Executive Officers

    BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

    11/17/23 9:00:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Shineco Inc.

    SC 13G/A - SHINECO, INC. (0001300734) (Subject)

    10/25/24 2:45:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Shineco Inc.

    SC 13D - SHINECO, INC. (0001300734) (Subject)

    7/12/24 5:28:03 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Shineco Inc.

    SC 13G - SHINECO, INC. (0001300734) (Subject)

    8/29/23 1:26:38 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care